Tool will enhance antibody-dependent cellular cytotoxicity in Takeda’s R&D.
Takeda Pharmaceutical has gained access to BioWa’s Potelligent® Technology platform for the development of antibody-dependent cellular cytotoxicity-enhanced (ADCC) antibodies.
The agreement grants Takeda nonexclusive rights to research, develop, manufacture, and commercialize antibodies based on this tool for an undisclosed number of targets. In return, BioWa will receive an upfront payment, license fees, development milestones, and royalties.
Potelligent Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, according to BioWa. Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.